|
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors Clinical research trials and Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors. Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors clinical trial. Participants frequently obtain the most expert healthcare available for their Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors  Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
For Condition: Brain Tumor
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Indiana University Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Inserting a specific gene into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus gene therapy in treating patients who have CNS tumors .
Details: OBJECTIVES: I. Determine the toxicity (detection of replication competent retrovirus) associated with CD34+ cells transduced with a retroviral vector expressing human O6-methylguanine DNA methyltransferase in adult and pediatric patients with poor prognosis CNS tumors. II. Determine the safety of genetic modification of cells carried out in the presence (ex vivo) of recombinant fibronectin (FN) fragment utilized to assist in retroviral entry into mammalian cells. III. Determine any evidence of engraftment of cells exposed to FN during retroviral transduction. IV. Determine any evidence of antibodies to FN following infusion of cells exposed to FN during ex vivo retroviral transduction. PROTOCOL OUTLINE: Patients with surgically approachable lesions undergo maximal surgical debulking that allows preservation of good neurologic functioning. Harvest: Patients receive filgrastim (G-CSF) subcutaneously or IV beginning 4 days prior to initiation of first leukapheresis and continuing until completion of harvest. Peripheral blood stem cells are harvested and selected for CD34+ cells which are transduced with a fibronectin assisted retroviral vector expressing human O6-methylguanine DNA methyltransferase. Intensification: Patients receive oral lomustine and vincristine IV on day 0 and oral procarbazine on days 1-7. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with newly diagnosed tumors may undergo involved field radiotherapy (IF-RT) after completion of the third course of chemotherapy and may begin the fourth course of chemotherapy after completion of IF-RT. Transplantation: Two-thirds of the transduced CD34+ cells are reinfused on day 9 of the first course of chemotherapy. The remaining portion (one-third) of the transduced CD34+ cells are reinfused on day 9 of the second course of chemotherapy. Untransduced CD34+ cells are reinfused on day 9 of the last 3 courses of chemotherapy. Patients are followed every 3 months for 6 months, every 4 months for 1 year, every 6 months through year 5, and then annually thereafter. PROJECTED ACCRUAL: Approximately 15-20 patients will be accrued for this study within 1 year.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 5 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven newly diagnosed CNS tumors; Eligible tumor types: Glioblastoma multiforme (WHO grade IV); Anaplastic astrocytoma (WHO grade III); Anaplastic oligodendroglioma (WHO grade III); Mixed anaplastic oligoastrocytoma (WHO grade III); Incompletely resected ependymoma; Diffusely intrinsic pontine or medullary glioma Histology requirement waived OR Histologically proven recurrent or progressive CNS tumors; Eligible tumor types: Same as above plus oligodendroglioma (WHO grade II) - No brainstem tumors arising from the cervicomedullary region or midbrain without histologic proof of malignancy - No supratentorial low grade astrocytomas (WHO grade I or II) --Prior/Concurrent Therapy-- - Biologic therapy: No growth factors after completion of study chemotherapy - Chemotherapy: No prior nitrosourea or procarbazine - Endocrine therapy: No concurrent dexamethasone as antiemetic - Radiotherapy: No prior craniospinal radiotherapy - Surgery: Not specified --Patient Characteristics-- - Age: 5 and over - Performance status: ECOG 0-2 - Life expectancy: At least 2 months - Hematopoietic: Absolute neutrophil count greater than 1,000/mm3; Platelet count greater than 100,000/mm3 (transfusion independent); Hemoglobin greater than 10 g/dL at time of pulmonary function testing - Hepatic: Bilirubin less than 1.2 mg/dL; SGOT or SGPT less than 3 times normal - Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance or radioisotope GFR greater than 70 mL/min - Pulmonary: FEV1, FVC, and/or DLCO greater than 60% predicted; Children who are uncooperative with pulmonary function tests must have the following: No evidence of dyspnea at rest; No exercise intolerance; Oxygen saturation (by pulse oximetry) greater than 94% on room air - Other: Minimum weight of 10 kg; Not pregnant or nursing; No active infection
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JamesCroop, Study Chair, Indiana University Cancer Center
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5265
United States
Additional Information:
Study ID Numbers: CDR0000067758; IUMC-9607-22,NCI-H00-0049
Study Start Date: February 2000
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005796
Other Brain Tumor Studies:
1. Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
2. Procarbazine in Treating Patients With Recurrent Brain Tumor
3. Amifostine to Protect From the Side Effects of Peripheral Stem Cell Transplantation in Treating Patients With High-Risk or Relapsed Solid Tumors
4. Melphalan in Patients With Neoplastic Meningitis
5. P-glycoprotein Antagonist, Tariquidar, in Combination with Doxorubicin (Adriamycin), Vinorelbine (Navelbine), or Docetaxel to Treat Children with Solid Tumors
Related Studies:
Other Brain Tumor Clinical Trials
Other Indiana Clinical Trials
Other Indianapolis Clinical Trials
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
|
|
|
|
|
|
|
|
